Literature DB >> 11865825

Hemodynamic consequences of neuropeptide Y-induced obesity.

Marcelo L G Correia1, Donald A Morgan, William I Sivitz, Allyn L Mark, William G Haynes.   

Abstract

BACKGROUND: Acute central nervous system administration of neuropeptide Y (NPY) elicits variable hemodynamic responses. Chronic intracerebroventricular (ICV) administration of NPY produces obesity in rats. Obesity has been shown to increase arterial pressure.
METHODS: In this study we examined the chronic hemodynamic effects of NPY-induced obesity. Sprague-Dawley rats were implanted with radiotelemetry transmitters to continuously record heart rate and arterial pressure in the conscious state. Neuropeptide Y or vehicle was delivered into the third cerebral ventricle by osmotic minipumps over 2 weeks. Three groups were studied: vehicle, NPY-treated (free-fed), and NPY-treated (pair-fed to vehicle-treated rats).
RESULTS: Neuropeptide Y increased food intake and body weight in free-fed animals, and substantially augmented visceral adiposity in both free- and pair-fed rats. Despite increased adiposity, chronic ICV administration of NPY in conscious unstressed rats did not increase arterial pressure. Neuropeptide Y decreased heart rate, suggesting a sympathoinhibitory effect.
CONCLUSIONS: Obesity induced by 2-week ICV administration of NPY does not increase arterial pressure, perhaps indicating inhibition of sympathetic outflow that may oppose the pressor effect of adiposity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865825     DOI: 10.1016/s0895-7061(01)02270-1

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

1.  Chronic central ghrelin infusion reduces blood pressure and heart rate despite increasing appetite and promoting weight gain in normotensive and hypertensive rats.

Authors:  John N Freeman; Jussara M do Carmo; Ahmad H Adi; Alexandre A da Silva
Journal:  Peptides       Date:  2013-02-13       Impact factor: 3.750

2.  Control of appetite, blood glucose, and blood pressure during melanocortin-4 receptor activation in normoglycemic and diabetic NPY-deficient mice.

Authors:  Alexandre A da Silva; J Nathan Freeman; John E Hall; Jussara M do Carmo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-12-20       Impact factor: 3.619

3.  Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: a pilot study.

Authors:  Maria Baltazi; Niki Katsiki; Christos Savopoulos; Fotios Iliadis; George Koliakos; Apostolos I Hatzitolios
Journal:  Am J Cardiovasc Dis       Date:  2011-05-20

Review 4.  Competing paradigms of obesity pathogenesis: energy balance versus carbohydrate-insulin models.

Authors:  David S Ludwig; Caroline M Apovian; Louis J Aronne; Arne Astrup; Lewis C Cantley; Cara B Ebbeling; Steven B Heymsfield; James D Johnson; Janet C King; Ronald M Krauss; Gary Taubes; Jeff S Volek; Eric C Westman; Walter C Willett; William S Yancy; Mark I Friedman
Journal:  Eur J Clin Nutr       Date:  2022-07-28       Impact factor: 4.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.